Clinical Trial: RIGENERA 2.0 Trial

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional



Official Title: RIGENERA 2.0 (Recupero Dall'Infarto Miocardico Con G-CSF E Nuovi Esempi di Rigenerazione Avanzata) Project: "The Combined Effect of Subcutaneous Granulocyte - Colony Stimulating Factor and Myocar

Brief Summary:

Study Objectives: To determine whether, in patients with large acute myocardial infarction undergoing primary or rescue angioplasty, the administration of subcutaneous Lenograstim [recombinant human Granulocyte-Colony Stimulating Factor (rhu G-CSF), Myelostim 34, Italfarmaco] associated with Myocardial Contrast Echocardiography and the intravenous infusion of sulphur hexafluoride (Sonovue, Bracco) determines an improvement:

  • in regional and global contractile function, myocardial perfusion and infarct size assessed by cardiovascular magnetic resonance.
  • Echocardiographic parameters of LV function
  • in the serum profile of inflammatory and mobilizing cytokines and of biomarkers of myocardial damage and wall stress